Ovarian Cancer Diagnostics Market by Types (Imaging [Ultrasound, CT Scan, MRI Scan, PET Scan, and Others], Blood Tests [CA125, HER2, BRCA, CEA, ER & PR, KRAS Mutation, and Others], Biopsy, and Others), Cancer Types (Epithelial Tumor, Stromal Cell Tumor, Germ Cell Tumor, and Others), End-users (Hospital Laboratories, Cancer Diagnostic Centers, Research Institutes, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The global ovarian cancer diagnostics market size is projected to expand at a substantial CAGR during the forecast period, 2021 – 2028. The growth of the market is attributed to the rising prevalence of ovarian cancer and increasing emphasis on wide adoption of its diagnosis & treatment.
Ovarian cancer is a specific type of cancer, which is only related to cancer formation in female organ. Among different types of ovarian cancer, the epithelial ovarian cancer is the most common one and this is one of the most leading causes of increasing mortality rate of women around the world. According to a public health data, it is the fifth leading cause of cancer death in women worldwide and the tenth common cause of cancer death among women in the US.
In general, the detection of ovarian cancer in the early stage remains difficult until it starts affecting other organs around the pelvis and stomach. Since most patients are diagnosed at an advanced stage, the disease's prognosis is still low. As a result, there is an urgent need for further research into disease biology in order to establish successful treatment options with the aim of overcoming resistance while minimizing toxicity. Furthermore, biomarker discovery is considered to be a key means for aiding in the effective identification of patients that need ongoing treatment. Bloating, irregular menstruation, menstrual bleeding, indigestion, and fatigue are some of the signs of the disorder. As per several scientific studies, a deeper understanding of the fundamental molecular processes is urgently needed in order to identify genetic elements or biochemical pathways that could be targeted for diagnosis and treatment.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing prevalence of ovarian cancer and rising awareness about the availability of advanced diagnostic devices are key factors driving the market growth.
- Rising healthcare expenditure and increasing technological advancements for effective diagnosis are expected to propel the market expansion during the forecast period.
- Several favorable governments’ programs and their increasing support for ovarian cancer research are expected to boost the market growth in the coming years.
- Lack of information about the exact origin and causative factors of the illness and late diagnosis of the disease are major challenges that can hamper the market growth.
- Ongoing R&D activities to expand the treatment and diagnostic technique are providing several key opportunities for the overall market expansion.
Scope of the Report
The report on the global ovarian cancer diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Ovarian Cancer Diagnostics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2020 |
|
Historic Data |
2018–2019 |
|
Forecast Period |
2021–2028 |
|
Segmentation |
Types (Imaging [Ultrasound, CT Scan, MRI Scan, PET Scan, and Others], Blood Tests [CA125, HER2, BRCA, CEA, ER & PR, KRAS Mutation, and Others], Biopsy, and Others), Cancer Types (Epithelial Tumor, Stromal Cell Tumor, Germ Cell Tumor, and Others), End-users (Hospital Laboratories, Cancer Diagnostic Centers, Research Institutes, and Others) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc; Johnson & Johnson Services, Inc.; AstraZeneca plc; Siemens Healthcare GmbH; Quest Diagnostics Incorporated.; Thermo Fisher Scientific; Bio-Rad Technologies Inc.; and Abbott. |
Ovarian Cancer Diagnostics Market Segment Insights
Imaging segment is expected to account for a large market share
Based on types, the global ovarian cancer diagnostics market is divided into imaging, blood test, biopsy, and others. The imaging segment is further classified as ultrasound, CT scan, MRI scan, PET scan, and others while the blood tests segment as CA125, HER2, BRCA, CEA, ER & PR, KRAS mutation, and others. The imaging segment is expected to account for a key share of the market owing to wide adoption of imaging method due to the growing importance of early detection and cancer staging. The preliminary imaging method also known as trans-vaginal ultrasound is widely adopted for detecting and measuring the size of a tumor internally. While CT scans are recommended for cancer staging, they are only appropriate for small tumors. To diagnose metastasis and the seriousness of the disease, more sophisticated imaging methods such as MRI and PET scans are used.
However, the blood test segment is anticipated to expand at a steady pace during the forecast period. With the rapid technological advances and growing customer awareness, the demand for blood tests is rising steadily over the years. Increased levels of certain biomarkers, which function as tumor markers and help in diagnosis, may occur as a result of ovarian cancer. The most common blood test for this disorder, for example, is CA-125. Greater market penetration for HER2, BRCA, and KRAS mutation tests have resulted to growing focus on genetic therapy and tests.
Epithelial Tumor segment is projected to constitute a major share
On the basis of cancer types, the market is segmented into epithelial tumor, stromal cell tumor, germ cell tumor, and others. The epithelial tumor segment is projected to constitute a major share of the market in the coming years and held more than 85% share of all ovarian malignancies in 2020. Serous, mucinous, endometrioid, and clear cell epithelial tumors are all types of epithelial tumors. The majority of epithelial cell carcinoma patients who are diagnosed after the tumor has spread to the peritoneal cavity. Around 70-80% of patients are diagnosed at an advanced stage, which leads to limiting care options and survival rates dramatically. Meanwhile, the germ cell and stromal cell tumors together is anticipated to account for a considerable share of the market in the coming years. Stromal tumors arise in the tissues that produce hormones including estrogen, progesterone, and testosterone. Germ cell tumors are mostly common in women who are between the aged of 20 to 30 years old, despite their rarity.
Research institute segment is expected to grow at rapid pace
Based on end-users, the global ovarian cancer diagnostics market is divided into hospital laboratories, cancer diagnostic centers, research institutes, and others. The hospital laboratories segment is expected to hold a large market share owing to increasing patient inflow for cancer diagnosis in hospitals. Moreover, rapid expansion of laboratory tests in hospitals present a key driving factor for the segment growth. However, the research institute segment is anticipated to expand at a rapid pace during the forecast period due to increasing investments towards healthcare research in collaboration with research institutes especially in developed regions. The Fred Hutchinson Cancer Research Center, for example, is focusing towards the discovery of biomarkers and ovarian cancer screening.
Asia Pacific market is anticipated to expand at a high CAGR
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Due to good commercial performances of gynecologic diagnostics especially in the US, North America accounted for more than 40.5 percent of the overall market share in 2020. Other factors contributing to the regional market growth include favorable government policies, a rise in healthcare spending, and the presence of key manufacturers. On the other hand, the market in Asia Pacific is projected to expand at a high CAGR during the forecast period due to factors such as economic growth, improved healthcare infrastructure, increased disposable income, and increased market awareness. Emerging markets such as China, India, and South Korea are expected to experience rapid growth in the ovarian cancer diagnostics market in the coming years.
Segments
Segments Covered in the ReportThe global ovarian cancer diagnostics market has been segmented on the basis of
Types
- Imaging
- Ultrasound
- CT Scan
- MRI Scan
- PET Scan
- Others
- Blood Tests
- CA125
- HER2
- BRCA
- CEA
- ER & PR
- KRAS Mutation
- Others
- Biopsy
- Others
- Epithelial Tumor
- Stromal Cell Tumor
- Germ Cell Tumor
- Others
- Hospital Laboratories
- Cancer Diagnostic Centers
- Research Institutes
- Others
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc.
- Johnson & Johnson Services, Inc.
- AstraZeneca plc
- Siemens Healthcare GmbH
- Quest Diagnostics Incorporated.
- Thermo Fisher Scientific
- Bio-Rad Technologies Inc.
- Abbott
Competitive Landscape
Some of the key players operating in the market are F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc; Johnson & Johnson Services, Inc.; AstraZeneca plc; Siemens Healthcare GmbH; Quest Diagnostics Incorporated.; Thermo Fisher Scientific; Bio-Rad Technologies Inc.; and Abbott. This market is increasingly competitive as major players concentrate more on strategic strategies including product launches, mergers and acquisitions, licencing alliances, and co-development deals. Foundation Medicine, for example, announced in June 2019 that its Foundation One CDx, a detailed genomic profiling test, had obtained the US Food and Drug Administration (FDA) approval for use as a companion diagnostic for LYNPARZA (Olaparib) in first-line maintenance therapy for BRCA-mutated metastatic ovarian cancer. BRCA1/2 mutations both germline and somatic, can be detected using this test.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Ovarian Cancer Diagnostic Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Ovarian Cancer Diagnostic Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Ovarian Cancer Diagnostic Market - Supply Chain
4.5. Global Ovarian Cancer Diagnostic Market Forecast
4.5.1. Ovarian Cancer Diagnostic Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Ovarian Cancer Diagnostic Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Ovarian Cancer Diagnostic Market Absolute $ Opportunity
5. Global Ovarian Cancer Diagnostic Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Ovarian Cancer Diagnostic Market Size and Volume Forecast by Types
5.3.1. Imaging
5.3.2. Blood Tests
5.3.3. Biopsy
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Ovarian Cancer Diagnostic Market Analysis and Forecast by End Users
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by End Users
6.2.2. Y-o-Y Growth Projections by End Users
6.3. Ovarian Cancer Diagnostic Market Size and Volume Forecast by End Users
6.3.1. Hospital Laboratories
6.3.2. Cancer Diagnostic Centers
6.3.3. Research Institutes
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by End Users
6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Ovarian Cancer Diagnostic Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Ovarian Cancer Diagnostic Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Ovarian Cancer Diagnostic Demand Share Forecast, 2019-2026
8. North America Ovarian Cancer Diagnostic Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Ovarian Cancer Diagnostic Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Ovarian Cancer Diagnostic Market Size and Volume Forecast by Types
8.4.1. Imaging
8.4.2. Blood Tests
8.4.3. Biopsy
8.4.4. Others
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. North America Ovarian Cancer Diagnostic Market Size and Volume Forecast by End Users
8.7.1. Hospital Laboratories
8.7.2. Cancer Diagnostic Centers
8.7.3. Research Institutes
8.7.4. Others
8.8. Basis Point Share (BPS) Analysis by End Users
8.9. Y-o-Y Growth Projections by End Users
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Ovarian Cancer Diagnostic Demand Share Forecast, 2019-2026
9. Latin America Ovarian Cancer Diagnostic Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Ovarian Cancer Diagnostic Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Ovarian Cancer Diagnostic Market Size and Volume Forecast by Types
9.4.1. Imaging
9.4.2. Blood Tests
9.4.3. Biopsy
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Latin America Ovarian Cancer Diagnostic Market Size and Volume Forecast by End Users
9.7.1. Hospital Laboratories
9.7.2. Cancer Diagnostic Centers
9.7.3. Research Institutes
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by End Users
9.9. Y-o-Y Growth Projections by End Users
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Ovarian Cancer Diagnostic Demand Share Forecast, 2019-2026
10. Europe Ovarian Cancer Diagnostic Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Ovarian Cancer Diagnostic Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Ovarian Cancer Diagnostic Market Size and Volume Forecast by Types
10.4.1. Imaging
10.4.2. Blood Tests
10.4.3. Biopsy
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Europe Ovarian Cancer Diagnostic Market Size and Volume Forecast by End Users
10.7.1. Hospital Laboratories
10.7.2. Cancer Diagnostic Centers
10.7.3. Research Institutes
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by End Users
10.9. Y-o-Y Growth Projections by End Users
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Ovarian Cancer Diagnostic Demand Share Forecast, 2019-2026
11. Asia Pacific Ovarian Cancer Diagnostic Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Ovarian Cancer Diagnostic Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Ovarian Cancer Diagnostic Market Size and Volume Forecast by Types
11.4.1. Imaging
11.4.2. Blood Tests
11.4.3. Biopsy
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Asia Pacific Ovarian Cancer Diagnostic Market Size and Volume Forecast by End Users
11.7.1. Hospital Laboratories
11.7.2. Cancer Diagnostic Centers
11.7.3. Research Institutes
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by End Users
11.9. Y-o-Y Growth Projections by End Users
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Ovarian Cancer Diagnostic Demand Share Forecast, 2019-2026
12. Middle East & Africa Ovarian Cancer Diagnostic Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Ovarian Cancer Diagnostic Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Ovarian Cancer Diagnostic Market Size and Volume Forecast by Types
12.4.1. Imaging
12.4.2. Blood Tests
12.4.3. Biopsy
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Middle East & Africa Ovarian Cancer Diagnostic Market Size and Volume Forecast by End Users
12.7.1. Hospital Laboratories
12.7.2. Cancer Diagnostic Centers
12.7.3. Research Institutes
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by End Users
12.9. Y-o-Y Growth Projections by End Users
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Ovarian Cancer Diagnostic Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Ovarian Cancer Diagnostic Market: Market Share Analysis
13.2. Ovarian Cancer Diagnostic Distributors and Customers
13.3. Ovarian Cancer Diagnostic Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. F. Hoffmann-La Roche Ltd.
13.4.2. GlaxoSmithKline plc.
13.4.3. Johnson & Johnson Services, Inc.
13.4.4. AstraZeneca plc
13.4.5. Siemens Healthcare GmbH
13.4.6. Quest Diagnostics Incorporated.
13.4.7. Thermo Fisher Scientific
2. Assumptions and Acronyms Used
3. Research Methodology
4. Ovarian Cancer Diagnostic Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Ovarian Cancer Diagnostic Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Ovarian Cancer Diagnostic Market - Supply Chain
4.5. Global Ovarian Cancer Diagnostic Market Forecast
4.5.1. Ovarian Cancer Diagnostic Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Ovarian Cancer Diagnostic Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Ovarian Cancer Diagnostic Market Absolute $ Opportunity
5. Global Ovarian Cancer Diagnostic Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Ovarian Cancer Diagnostic Market Size and Volume Forecast by Types
5.3.1. Imaging
5.3.2. Blood Tests
5.3.3. Biopsy
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Ovarian Cancer Diagnostic Market Analysis and Forecast by End Users
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by End Users
6.2.2. Y-o-Y Growth Projections by End Users
6.3. Ovarian Cancer Diagnostic Market Size and Volume Forecast by End Users
6.3.1. Hospital Laboratories
6.3.2. Cancer Diagnostic Centers
6.3.3. Research Institutes
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by End Users
6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Ovarian Cancer Diagnostic Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Ovarian Cancer Diagnostic Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Ovarian Cancer Diagnostic Demand Share Forecast, 2019-2026
8. North America Ovarian Cancer Diagnostic Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Ovarian Cancer Diagnostic Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Ovarian Cancer Diagnostic Market Size and Volume Forecast by Types
8.4.1. Imaging
8.4.2. Blood Tests
8.4.3. Biopsy
8.4.4. Others
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. North America Ovarian Cancer Diagnostic Market Size and Volume Forecast by End Users
8.7.1. Hospital Laboratories
8.7.2. Cancer Diagnostic Centers
8.7.3. Research Institutes
8.7.4. Others
8.8. Basis Point Share (BPS) Analysis by End Users
8.9. Y-o-Y Growth Projections by End Users
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Ovarian Cancer Diagnostic Demand Share Forecast, 2019-2026
9. Latin America Ovarian Cancer Diagnostic Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Ovarian Cancer Diagnostic Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Ovarian Cancer Diagnostic Market Size and Volume Forecast by Types
9.4.1. Imaging
9.4.2. Blood Tests
9.4.3. Biopsy
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Latin America Ovarian Cancer Diagnostic Market Size and Volume Forecast by End Users
9.7.1. Hospital Laboratories
9.7.2. Cancer Diagnostic Centers
9.7.3. Research Institutes
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by End Users
9.9. Y-o-Y Growth Projections by End Users
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Ovarian Cancer Diagnostic Demand Share Forecast, 2019-2026
10. Europe Ovarian Cancer Diagnostic Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Ovarian Cancer Diagnostic Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Ovarian Cancer Diagnostic Market Size and Volume Forecast by Types
10.4.1. Imaging
10.4.2. Blood Tests
10.4.3. Biopsy
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Europe Ovarian Cancer Diagnostic Market Size and Volume Forecast by End Users
10.7.1. Hospital Laboratories
10.7.2. Cancer Diagnostic Centers
10.7.3. Research Institutes
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by End Users
10.9. Y-o-Y Growth Projections by End Users
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Ovarian Cancer Diagnostic Demand Share Forecast, 2019-2026
11. Asia Pacific Ovarian Cancer Diagnostic Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Ovarian Cancer Diagnostic Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Ovarian Cancer Diagnostic Market Size and Volume Forecast by Types
11.4.1. Imaging
11.4.2. Blood Tests
11.4.3. Biopsy
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Asia Pacific Ovarian Cancer Diagnostic Market Size and Volume Forecast by End Users
11.7.1. Hospital Laboratories
11.7.2. Cancer Diagnostic Centers
11.7.3. Research Institutes
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by End Users
11.9. Y-o-Y Growth Projections by End Users
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Ovarian Cancer Diagnostic Demand Share Forecast, 2019-2026
12. Middle East & Africa Ovarian Cancer Diagnostic Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Ovarian Cancer Diagnostic Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Ovarian Cancer Diagnostic Market Size and Volume Forecast by Types
12.4.1. Imaging
12.4.2. Blood Tests
12.4.3. Biopsy
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Middle East & Africa Ovarian Cancer Diagnostic Market Size and Volume Forecast by End Users
12.7.1. Hospital Laboratories
12.7.2. Cancer Diagnostic Centers
12.7.3. Research Institutes
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by End Users
12.9. Y-o-Y Growth Projections by End Users
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Ovarian Cancer Diagnostic Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Ovarian Cancer Diagnostic Market: Market Share Analysis
13.2. Ovarian Cancer Diagnostic Distributors and Customers
13.3. Ovarian Cancer Diagnostic Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. F. Hoffmann-La Roche Ltd.
13.4.2. GlaxoSmithKline plc.
13.4.3. Johnson & Johnson Services, Inc.
13.4.4. AstraZeneca plc
13.4.5. Siemens Healthcare GmbH
13.4.6. Quest Diagnostics Incorporated.
13.4.7. Thermo Fisher Scientific
Segments Covered in the Report
The global ovarian cancer diagnostics market has been segmented on the basis of
Types
The global ovarian cancer diagnostics market has been segmented on the basis of
Types
- Imaging
- Ultrasound
- CT Scan
- MRI Scan
- PET Scan
- Others
- Blood Tests
- CA125
- HER2
- BRCA
- CEA
- ER & PR
- KRAS Mutation
- Others
- Biopsy
- Others
- Epithelial Tumor
- Stromal Cell Tumor
- Germ Cell Tumor
- Others
- Hospital Laboratories
- Cancer Diagnostic Centers
- Research Institutes
- Others
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc.
- Johnson & Johnson Services, Inc.
- AstraZeneca plc
- Siemens Healthcare GmbH
- Quest Diagnostics Incorporated.
- Thermo Fisher Scientific
- Bio-Rad Technologies Inc.
- Abbott
Some of the key players operating in the market are F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc; Johnson & Johnson Services, Inc.; AstraZeneca plc; Siemens Healthcare GmbH; Quest Diagnostics Incorporated.; Thermo Fisher Scientific; Bio-Rad Technologies Inc.; and Abbott. This market is increasingly competitive as major players concentrate more on strategic strategies including product launches, mergers and acquisitions, licencing alliances, and co-development deals. Foundation Medicine, for example, announced in June 2019 that its Foundation One CDx, a detailed genomic profiling test, had obtained the US Food and Drug Administration (FDA) approval for use as a companion diagnostic for LYNPARZA (Olaparib) in first-line maintenance therapy for BRCA-mutated metastatic ovarian cancer. BRCA1/2 mutations both germline and somatic, can be detected using this test.
Our Clients
Related Reports
Some other reports from this category!
